Skip to main content
Clinical Trials/ITMCTR2100004300
ITMCTR2100004300
Recruiting
Phase 1

Trigger point dry needling in the treatment of postherpetic neuralgia: a prospective, randomized controlled study

The First Affiliated Hospital of Jinan University0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
postherpetic neuralgia
Sponsor
The First Affiliated Hospital of Jinan University
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
The First Affiliated Hospital of Jinan University

Eligibility Criteria

Inclusion Criteria

  • (1\) The diagnosis of postherpetic neuralgia was based on the Chinese Expert Consensus on the Diagnosis and Treatment of postherpetic neuralgia.
  • (2\) Visual analogue scale(VAS) of pain score above 4\.
  • (3\) No contraindications or intolerable adverse reactions to neuropathic pain drugs, such drugs include: pregabalin, amitriptyline, opioids (tramadol, morphine, oxycodone, etc.).
  • (4\) Premenopausal women are willing to confirm birth control measures during the trial.
  • (5\) No other treatment will be given during the trial.
  • (6\) Have normal comprehension and expression ability.

Exclusion Criteria

  • (1\) Patients with other severe chronic pain.
  • (2\) Initiate additional treatment during the trial.
  • (3\) The patient is pregnant or nursing.
  • (4\) Patients with drug or alcohol dependence.
  • (5\) Mental illness that affects patients' judgment or interferes with the conduct of the trial.
  • (6\) Unwilling to accept the review or unable to understand the scale measurement.
  • (7\) Patients with nausea tumor (except patients without recurrence 6 months after radical surgery).
  • (8\) Patients with abnormal coagulation function.
  • (9\) Patients with acute thrombotic events: ischemic stroke, myocardial infarction, pulmonary embolism, deep venous thrombosis, etc.
  • (10\) Unstable angina pectoris.

Outcomes

Primary Outcomes

Not specified

Similar Trials